Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Monique Verschuren
Statins for the primary prevention of cardiovascular disease Taylor F, Ward K, Moore THM et al Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD004816.
Statins are known to lower the risk of cardiovascular diseases (CVD). The majority of trials has focused on the use of statins for secondary prevention, but the benefits of using statins in primary prevention are less clear. This review has identified 14 randomised controlled trials in persons without a history of CVD, including almost 35,000 persons. The conclusion is that also in primary prevention, a significant lowering of cardiovascular endpoints is observed: a 17% reduction in all-cause mortality, a 30% reduction in the combined endpoint of fatal and non-fatal CVD and a 34% reduction in revascularization rates. No adverse effects were observed. Only one trial reported on costs, and no trial reported on quality of life. Therefore, information on cost-effectiveness of treating individuals without a history of CVD is still lacking. It also has to be noted that the majority of the participants in these trials were white, male and middle-aged. Therefore, we need to be cautious in applying the results to older people, who may be at greater risk of side effects, and to women, who are at lower risk of CVD events.
© 2017 European Society of Cardiology. All rights reserved